Review articleThe role of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like effect
Introduction
Major depressive disorder (MDD) is common and serious problem in modern society, and is responsible for disability worldwide. Sadness, lost of interest or pleasure, disturbed sleep and appetite, feelings of tiredness, low self-esteem or poor concentration are one of the main depressive symptoms, which strongly impair the individual's ability to function or cope with daily life, and sometimes can even lead to suicide. Currently one in four people in the world is affected by depression [1]. It is assumed that until 2020 it will be the second most commonly diagnosed disease in the world, just after ischaemic heart disease [1]. Despite the fact that there are many available antidepressants and possible therapies, there is still a problem with the efficacy of the treatment. It is very likely that this problem is associated with the complexity, and still not fully understood pathomechanism of the disease.
Since 1965 the monoaminergic theory of depression was considered as the main and only cause of the illness. This hypothesis assumed that MDD is connected with serotonin (5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine; NA) deficits in different parts of the brain, and therefore the enhancement of serotonergic and noradrenergic neurotransmission, will result in the improvement of the common symptoms of the disease [2]. Over the years this theory has evolved, and many new approaches appeared. Scientists noticed the strong relationship between depressive state and changes in various systems not only serotonergic and noradrenergic but also dopaminergic, cholinergic, glutamatergic, GABA-ergic or hypothalamic–pituitary–adrenal (HPA) axis dysregulation. This review will discuss the role and involvement of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like (AD-like) effect.
Section snippets
Animal tests and models of depression
First and foremost, it should be clarified that there is a difference between a test and a model of depression. A model includes both an independent variable (induced manipulation), and a dependent variable (behavioural/neurochemical readout), while a test simply comprises the latter variable [3], [4].
There are two commonly used tests to assess AD-like activity – forced swim test (FST) and tail suspension test (TST). Both are based on the observation that when rodents are subjected to an
Serotonergic system
Fluoxetine, the first selective 5-HT reuptake inhibitor (SSRI) was introduced in 1987 and its unique properties, appropriate clinical efficacy, and lower toxicity in comparison with the monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) overshadowed the previous pharmacological strategies, and emphasized the role of 5-HT in the MDD [33]. 5-HT is a monoamine neurotransmitter, which receptors emerged in the early stages of embryogenesis, and are distributed widespread in
5-HT1A receptors
Accumulating data have shown that agonists and antagonists of the 5HT1A receptors, as well as genetically modified mice lacking this subtype of receptor demonstrated AD-like activity in the several rodent tests and models of depression [20]. Agonists and even partial agonists of 5-HT1A produced AD-like effects after chronic administration, e.g. flesixonan in OB, buspirone in the CMS, 8-OH-DPAT and buspirone in the FST (in rats), VN2222 in the LH paradigm [61], [62], [63]. It is believed that
The role of the ionotropic 5-HT3 receptors in AD-like effect
A large body of evidence demonstrated that the 5-HT3 receptor antagonists, e.g. ondansetron, dolasetron and tropisetron, produced AD-like response in several rodents tests and models of depression [24]. On the contrary, 5-HT3 agonists, reduced the action of antidepressants in the FST in rats [103]. Furthermore, it is well known that the mechanism of action of fluoxetine and other antidepressants, is connected with the non-competitive antagonism of the 5-HT3 receptor [20]. The results reported
Noradrenergic system
The noradrenergic system is also involved in the pathophysiology of depression. MDD seems to be associated with a hypofunction of the noradrenergic system at least in part, so some antidepressants act by increasing the synaptic availability of NA [108]. Adrenergic receptors (α and β subtypes) are the basic targets of endogenous neurotransmitters NA and adrenaline, especially in mediating sympathetic activation to peripheral organs, but also in central nervous system (CNS). In addition,
Dopaminergic system
DA belongs to catecholamines alongside epinephrine and NA. It is not only a precursor of the latters, but also exerts its physiological effect [40]. DA receptors are G protein-coupled ones; they are expressed, inter alia, in the CNS. Two families amongst them are distinguished: D1-like comprising D1 and D5 receptors and D2-like consisting of D2, D3 and D4 [40], [153]. D1-like receptors are coupled to the Gs protein, hence their stimulation leads to the activation of AC and biosynthesis of cAMP.
Conclusions
This review presents data on some important findings concerning the involvement of serotonergic, noradrenergic and dopaminergic receptors in AD-like effect. Based on scientific reports we were able to confirm the role and the importance of these three neurotransmission pathways in depression's aetiology. Data indicate the significant changes in the functioning and sensitivity of 5-HT, α-, β- and DA receptors in depressive patients. Moreover, many preclinical evidences clearly suggest the
Funding
This work was supported by Jagiellonian University grant number K/DSC/001955.
Conflict of interest
All the authors declare no conflict of interest.
Acknowledgement
Karolina Podkowa is a holder of scholarship from the KNOW sponsored by Ministry of Science and Higher Education, Poland.
References (180)
- et al.
The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice
Neurosci Biobehav Rev
(2005) - et al.
Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: the involvement of serotonergic system
Pharmacol Rep
(2015) - et al.
Behavioural despair in rats: a new model sensitive to antidepressant treatments
Eur J Pharmacol
(1978) Role of the serotonergic system in the forced swimming test
Neurosci Biobehav Rev
(1995)- et al.
Effects of MK-801 and antidepressant drugs in the forced swimming test in rats
Eur Neuropsychopharmacol
(1992) Serotonin neurons, neuroplasticity, and homeostasis of neural tissue
Neuropsychopharmacology
(1999)- et al.
A review of central 5-HT receptors and their function
Neuropharmacology
(1999) - et al.
Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors
Brain Res Mol Brain Res
(1994) - et al.
3B but which 3B and that's just one of the questions: the heterogeneity of human 5-HT3 receptors
Trends Pharmacol Sci
(2008) - et al.
Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims
Neuropsychopharmacology
(2001)
Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine
Neuropsychopharmacology
Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol
Brain Res
Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635
Brain Res
Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter
J Psychiatr Res
The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat
Eur Neuropsychopharmacol
The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression
Neuropharmacology
Antidepressant-like activity of compounds with varying efficacy at 5-HT1A receptors
Neuropharmacology
Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists
Trends Neurosci
Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test
Neurosci Biobehav Rev
A genetic rat model of depression, Flinders sensitive line, has a lower density of 5-HT(1A) receptors, but a higher density of 5-HT(1B) receptors, compared to control rats
Neurochem Int
Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test
Eur J Pharmacol
Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical a
Neuropharmacology
1-(3-Trifluoromethylphenyl) piperazine (TFMPP) in the ventral tegmental area reduces the effect of desipramine in the forced swimming test in rats: possible role of serotonin receptors
Eur J Pharmacol
Preclinical pharmacology of FG5893: a potential anxiolytic drug with high affinity for both 5-HT1A and 5-HT2A receptors
Eur J Pharmacol
The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats
Neurosci Lett
The Flinders sensitive line rats, a genetic model of depression, show abnormal serotonin receptor mRNA expression in the brain that is reversed by 17beta-estradiol
Brain Res Mol Brain Res
Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment
Neuropharmacology
Chronic fluvoxamine treatment changes 5-HT(2A/2C) receptor-mediated behavior in olfactory bulbectomized mice
Life Sci
Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action
Neuron
Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: short- and long-term memory
Behav Brain Res
Changes in 5-HT4 receptor and 5-HT transporter binding in olfactory bulbectomized and glucocorticoid receptor heterozygous mice
Neurochem Int
Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression
Neuropharmacology
The catecholamine hypothesis of affective disorders: a review of supporting evidence
Am J Psychiatry
The ups and downs of modelling mood disorders in rodents
ILAR J
Animal models of psychiatric disorders
Forced swimming test in mice: a review of antidepressant activity
Psychopharmacology (Berl)
The antidepressant-like activity of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one involves serotonergic 5-HT1A and 5-HT2A/C receptors activation
Eur J Pharmacol
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors
J Psychiatry Neurosci
Active behaviours produced by antidepressants and opioids in the mouse tail suspension test
Int J Neuropsychopharmacol
Effect of citalopram in the modified forced swim test in rats
Pharmacol Rep
Behavioral despair in mice: a primary screening test for antidepressants
Arch Int Pharmacodyn Thér
Action of serotoninmimetics in the behavioral despair test in rats
Commun Psychopharmacol
Behavioral pharmacological properties of the novel antidepressant paroxetine, a selective 5-HT uptake inhibitor
Nihon Yakurigaku Zasshi
Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants
Psychopharmacology (Berl)
The tail suspension test: a new method for screening antidepressants in mice
Psychopharmacology (Berl)
The role of serotonin receptor subtypes in treating depression: a review of animal studies
Psychopharmacology (Berl)
Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior
Neuropsychopharmacology
Animal models of neuropsychiatric diseases, animal models of depression
Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation
Psychopharmacology (Berl)
Cited by (65)
The role of serotonergic and catecholaminergic systems for possible antidepressant activity of apigenin
2022, Saudi Journal of Biological SciencesThe rich pharmacological activities of Magnolia officinalis and secondary effects based on significant intestinal contributions
2021, Journal of EthnopharmacologyCitation Excerpt :The mixture of magnolol and honokiol (HMM) increased the level of 5-HT in the mouse prefrontal cortex to exert antidepression effects, regulated biochemical abnormalities in brain 5-HT and 5-hydroxyindoleacetic acid (5-HIAA), depressed the hypothalamic-pituitary-adrenal axis (HPA) hyperactive and the cyclic adenosine monophosphate (cAMP) pathway (Xu et al., 2008; Yi et al., 2009). The therapeutic effect was enhanced when HMM was combined with ginger volatile oil (Engleman et al., 1995; Gándara et al., 2005; Pytka et al., 2016; Qiang et al., 2009). In compound preparation, Banxia Houpu decoction, HMM and rhizome pinelliae provided a synergistic antidepressant effect by increasing the levels of 5-HT and DA in the prefrontal cortex (Yi et al., 2010).
Antidepressant-like effect of hydroalcoholic extract from barks of Rapanea ferruginea: Role of monoaminergic system and effect of its isolated compounds myrsinoic acid A and B
2020, Behavioural Brain ResearchCitation Excerpt :Clinical investigations have suggested the use of D2 receptor agonists for the MDD treatment and studies in depressive patients, including after-death, have shown a reduction in the concentration of metabolites of DA in cerebrospinal fluid and in other regions, which mediate mood [34,43]. It is also reporting in the literature that the depressive symptoms most related to DA are anhedonia and loss of motivation, which involve the reduction of dopaminergic signaling, especially in the mesolimbic dopaminergic pathway [33]. Pretreatment with SCH23390 (D1 receptor antagonist) or pimozide (D2 receptor antagonist) promoted a reversal of the antidepressant-like effect of HEBRF.
Therapeutic potential of dietary flavonoid hyperoside against non-communicable diseases: targeting underlying properties of diseases
2024, Critical Reviews in Food Science and NutritionThe pharmacological bases for repurposing statins in depression: a review of mechanistic studies
2023, Translational Psychiatry